Effects of exogenous relaxin on dry eye in an experimental Sjögren's disease (SS) mouse model.

IF 3.1 2区医学 Q1 OPHTHALMOLOGY

Experimental eye research Pub Date : 2026-10-12 DOI:10.1016/j.exer.2026.111280

Lucimeire N Carvalho, Taís H Wakamatsu, Cristiane D Gil, Gustavo B Gasparetto, Alex M Nasare, Eduarda de Oliveira, Larissa R Rosa, Priscila C Cristovam, José A P Gomes

{"title":"Effects of exogenous relaxin on dry eye in an experimental Sjögren's disease (SS) mouse model.","authors":"Lucimeire N Carvalho, Taís H Wakamatsu, Cristiane D Gil, Gustavo B Gasparetto, Alex M Nasare, Eduarda de Oliveira, Larissa R Rosa, Priscila C Cristovam, José A P Gomes","doi":"10.1016/j.exer.2026.111280","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the potential of exogenous relaxin (RLX) as a treatment for dry eye disease (DED) in an experimental animal model of Sjögren's disease (SS).Methods: Nonobese diabetic female (NOD) mice with SS-associated DED received RLX-based or vehicle eye drops (100 ng/mL) four times daily for 30 days. Clinical evaluations included measurements of tear production, assessment of keratitis, and histological analysis of the exorbital lacrimal gland. Inflammatory cytokine expression was measured using PCR.Results: RLX-treated mice showed significant improvement in tear production and keratitis reversal. Qualitative histological analysis suggested better preservation of lacrimal gland architecture, with more evident acinar and ductal structures in the RLX-treated group. PCR analysis demonstrated reduced inflammatory cytokine expression (IL-1β, IL-6, IL-12a, IL-17a, TNFα, and IFNγ), and increased expression of RLX and its receptor RXFP1 in the RLX-treated group.Conclusions: Exogenous relaxin shows therapeutic potential for DED in SS, demonstrated by clinical improvements and reduced inflammatory markers in an animal model of SS.","PeriodicalId":12177,"journal":{"name":"Experimental eye research","volume":" ","pages":"111280"},"PeriodicalIF":3.1000,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental eye research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.exer.2026.111280","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the potential of exogenous relaxin (RLX) as a treatment for dry eye disease (DED) in an experimental animal model of Sjögren's disease (SS).

Methods: Nonobese diabetic female (NOD) mice with SS-associated DED received RLX-based or vehicle eye drops (100 ng/mL) four times daily for 30 days. Clinical evaluations included measurements of tear production, assessment of keratitis, and histological analysis of the exorbital lacrimal gland. Inflammatory cytokine expression was measured using PCR.

Results: RLX-treated mice showed significant improvement in tear production and keratitis reversal. Qualitative histological analysis suggested better preservation of lacrimal gland architecture, with more evident acinar and ductal structures in the RLX-treated group. PCR analysis demonstrated reduced inflammatory cytokine expression (IL-1β, IL-6, IL-12a, IL-17a, TNFα, and IFNγ), and increased expression of RLX and its receptor RXFP1 in the RLX-treated group.

Conclusions: Exogenous relaxin shows therapeutic potential for DED in SS, demonstrated by clinical improvements and reduced inflammatory markers in an animal model of SS.

查看原文本刊更多论文

外源性松弛素对实验性Sjögren's病（SS）小鼠干眼的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental eye research 医学-眼科学

CiteScore

6.80

自引率

5.90%

发文量

323

审稿时长

66 days

期刊介绍： The primary goal of Experimental Eye Research is to publish original research papers on all aspects of experimental biology of the eye and ocular tissues that seek to define the mechanisms of normal function and/or disease. Studies of ocular tissues that encompass the disciplines of cell biology, developmental biology, genetics, molecular biology, physiology, biochemistry, biophysics, immunology or microbiology are most welcomed. Manuscripts that are purely clinical or in a surgical area of ophthalmology are not appropriate for submission to Experimental Eye Research and if received will be returned without review.